- Trial Phase
- Approved and marketed (anaphylaxis/Type I allergic reactions); Phase 2b expansion for chronic spontaneous urticaria
- Time to Market
- Already on the market — FDA approved Aug 9, 2024; label expanded March 2026 to all patients ≥33 lbs (no age cap); approved in Canada April 2026. The separate CSU (urticaria) indication is in Phase 2b and years from approval.
- Why 4/10
- neffy is already FDA-approved and commercializing (Aug 2024), so its defining binary has passed; the next hard, dated events are the Phase 2b chronic-spontaneous-urticaria interim readout expected Q4 2026 (a mid-stage secondary program) and the CVS Caremark formulary coverage decision now targeted for January 2027 — a payer/formulary outcome, not a regulatory binary, so per the rubric the score stays in the approved-drug 3-5 band at 4.
The single biggest swing factor is the CVS Caremark neffy coverage decision, now targeted for January 2027 — the stock lost 23.9% in one day merely on the deferral, so a favorable January outcome could be a major re-rating catalyst and another delay a fresh leg down. Also watch the Q4 2026 Phase 2b CSU interim readout (new-indication upside) and quarterly neffy sales vs the heavy SG&A burn; analysts' ~$23 mean target is far above the ~$6.38 price, but litigation over coverage-timing disclosures is an unresolved overhang.
Price Chart
Executive Summary
neffy (epinephrine nasal spray, development code ARS-1) is the first FDA-approved needle-free epinephrine for Type I allergic reactions including anaphylaxis, approved Aug 2024 and now labeled for everyone weighing ≥33 lbs with no age cap (March 2026), plus approved in Canada (April 2026). Developer ARS Pharmaceuticals (Nasdaq: SPRY) is a single-product company ramping sales — US neffy net product revenue was $72.2M in FY2025, $17.5M in Q1 2026 (+125% YoY) and $26.2M in Q2 2026 — but it holds only ~5% of the total US epinephrine market for Type 1 allergies. The big overhang: CVS Caremark deferred its neffy coverage decision to January 2027, the stock fell 23.9% on June 25, 2026 when that was disclosed, and multiple securities class actions followed; the stock trades near $6.38 versus a $23.25 mean analyst price target.
How It Works
Epinephrine is the standard emergency medicine for severe allergic reactions (anaphylaxis) — it quickly reverses airway swelling, hives and blood-pressure collapse by tightening blood vessels and relaxing airway muscles. neffy delivers the same drug as a spray mist into the nose instead of a needle auto-injector (like EpiPen), making emergency treatment needle-free and potentially easier for patients, parents and schools to administer.
Trial Status
Original FDA approval Aug 9, 2024; supplemental FDA approval March 5, 2025; sNDA approval March 31, 2026 removing the age requirement from neffy 1 mg for children/adults ≥33 lbs; Health Canada approval April 15, 2026. The Phase 2b CSU interim-analysis population was fully enrolled as of Q1 2026, with data expected Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- CVS Caremark neffy formulary/coverage decision — deferred, now targeted for January 2027 (key binary for the stock)
- Phase 2b chronic spontaneous urticaria (CSU) interim data expected Q4 2026 — new-indication readout for intranasal epinephrine
- Q3 2026 earnings (typically ~November) — neffy sales trajectory, cash burn and any payer-update commentary
- Securities class-action developments and the AptarGroup device litigation as potential headline risk
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARS Pharmaceuticals, Inc. COURT-RULING SPRY ·Originating report